Altamira Therapeutics announces transition from Nasdaq to OTC markets

Altamira Therapeutics (CYTO) announced that on December 18, 2024 it received notice that the Nasdaq Hearings Panel had determined to delist the Company’s common shares from The Nasdaq Stock Market due to the Company’s failure to comply with Rule 5550(a)(2) of Nasdaq’s Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share. The Company’s common shares will be delisted from Nasdaq at the open of trading on December 20, 2024 and are expected to then begin trading on the OTCQB marketplace under the ticker symbol “CYTOF.”